In the BioHarmony Drug Report Database

"Preview" Icon

Ambrisentan

Letairis, Volibris (ambrisentan) is a small molecule pharmaceutical. Ambrisentan was first approved as Letairis on 2007-06-15. It is used to treat pulmonary hypertension in the USA. It has been approved in Europe to treat pulmonary hypertension. The pharmaceutical is active against endothelin-1 receptor. In addition, it is known to target endothelin receptor type B. Letairis’s patents are valid until 2031-10-14 (FDA).

 

Trade Name

 

Volibris
 

Common Name

 

ambrisentan
 

ChEMBL ID

 

CHEMBL1111
 

Indication

 

pulmonary hypertension
 

Drug Class

 

Endothelin receptor antagonists

Image (chem structure or protein)

Ambrisentan structure rendering